# OnCo record rejuv-tx-secondary-t-cell-malignancy (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-tx-secondary-t-cell-malignancy/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-tx-secondary-t-cell-malignancy" ;
  schema:name "Secondary T-cell malignancy after CAR-T, and what the FDA's 2024 action actually says"@en ;
  schema:alternateName "boxed warning CAR-T"@en, "T cell lymphoma after CAR-T"@en, "secondary primary malignancy after CAR T"@en, "CAR-positive lymphoma"@en ;
  schema:description "In 2024 the US regulator added a warning to every approved CAR-T product about T-cell cancers after treatment. It says the risk applies to the class, that these can appear within weeks, and that patients should be monitored for life. It does not say CAR-T causes most of them, and published series find them very rare."@en ;
  schema:url <https://onco.cc/technologies/rejuv-tx-secondary-t-cell-malignancy/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell> ;
  schema:citation <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed>, <https://doi.org/10.1056/NEJMp2400209>, <https://doi.org/10.1038/s41591-024-02826-w>, <https://doi.org/10.3324/haematol.2026.301592>, <https://doi.org/10.1056/NEJMoa2411507> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "transplant", "cell-therapy", "second-cancer" ;
  onco:related <https://onco.cc/technologies/rejuv-tx-gene-modified-follow-up/>, <https://onco.cc/technologies/rejuv-tx-second-cancers/>, <https://onco.cc/technologies/rejuv-tx-prolonged-cytopenias/>, <https://onco.cc/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/>, <https://onco.cc/technologies/rejuv-tx-icans-and-neurocognition/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:terms <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .